sirolimus has been researched along with Amputation--Traumatic* in 2 studies
1 review(s) available for sirolimus and Amputation--Traumatic
Article | Year |
---|---|
The Spanish experience with hand, forearm, and arm transplantation.
This article summarizes the findings from 3 recipients of hand allografts, including a description of the preparatory surgery and the transplant and secondary procedures to enhance the function of the hand, forearm, and arm allografts. The study focuses on the complications and disability reported by each patient, with a minimum follow-up of 2 years. The few complications were controlled successfully with medical treatment. Hand transplantation is a major reconstructive procedure that requires careful medical follow-up. The authors provide the first report of a significant improvement in disabilities of the upper limb as a result of hand allotransplantation. Topics: Amputation, Traumatic; Arm; Arm Injuries; Forearm; Forearm Injuries; Hand Injuries; Hand Transplantation; Health Status Indicators; Humans; Immunosuppressive Agents; Program Development; Recovery of Function; Retrospective Studies; Sirolimus; Spain; Transplantation, Homologous; Treatment Outcome | 2011 |
1 other study(ies) available for sirolimus and Amputation--Traumatic
Article | Year |
---|---|
Bone healing after secondary surgery on hand allografts under sirolimus-based maintenance immunosuppression.
Composite tissue allograft transplantation is a recognized option for reconstruction in upper limb amputees. Sirolimus is an immunosuppressive drug that prevents organ rejection and improves kidney function, but its use has been associated with impaired healing. Two recipients of bilateral hand allografts underwent arthrodeses of 6 joints as secondary procedures while being treated with sirolimus. We found no clinical or radiologic evidence of bone healing delay or bone nonunion. The functional evaluation revealed an improvement in the performance of activities of daily living after the transplant and secondary procedures. We conclude that bone surgery can be performed safely in recipients of hand allografts who are receiving sirolimus-based immunosuppressive therapy. Topics: Adult; Amputation, Traumatic; Arm Injuries; Arthrodesis; Bone and Bones; Carpometacarpal Joints; Female; Graft Survival; Hand Transplantation; Humans; Immunosuppressive Agents; Male; Metacarpophalangeal Joint; Middle Aged; Sirolimus; Wound Healing; Wrist Joint | 2011 |